Determinants for Thyroid Hormone Replacement Therapy in Subclinical Hypothyroidism: A Multicenter Electronic Health Records-Based Study

• Published in: Thyroid (New York, N.Y.) Vol. 33; no. 9; p. 1045
• Main Authors: Toloza, Freddy J K, El Kawkgi, Omar M, Spencer, Horace J, Mathews, Sherin Elsa, Garcia, Andrea, Gamboa, Augusto, Mirza, Nabeel, Mohan, Sneha, Vallejo, Sebastian, Bogojevic, Marija, Rodriguez-Gutierrez, Rene, Singh Ospina, Naykky M, Brito, Juan P, Maraka, Spyridoula
• Format: Journal Article
• Language: English
• Published: United States 01-09-2023
• Subjects: Adult; Electronic Health Records; Female; Hormone Replacement Therapy; Humans; Hypothyroidism - diagnosis; Male; Thyrotropin - therapeutic use; Thyroxine - therapeutic use; levothyroxine; autoimmunity; thyroid; subclinical hypothyroidism
• ISSN: 1557-9077
• DOI: 10.1089/thy.2023.0062

The frequency and factors associated with thyroid hormone replacement therapy among patients with subclinical hypothyroidism (SCH) remain uncertain.
In this electronic health records-based observational cohort study, we included adults diagnosed with SCH from four academic centers (the United States and Mexico) from January 1, 2016, to December 31, 2018. We aimed to identify the determinants of thyroid hormone replacement therapy for SCH and the frequency of treated SCH.
A total of 796 patients (65.2% women) had SCH, and 165 (20.7%) were treated with thyroid hormone replacement therapy. The treated group was younger [51.0 (standard deviation {SD} 18.3) vs. 55.3 (SD 18.2) years,
 = 0.008] and had a higher proportion of women (72.7% vs. 63.2%,
 = 0.03) compared with the untreated group. Only 46.7% of patients in the treated group and 65.6% in the untreated group had confirmatory thyroid function tests (TFTs) before the decision to start thyroid hormone replacement therapy was made. There was no difference in the frequency of thyroid autoimmunity evaluation, but a positive thyroid autoimmunity test was more frequent in the treated group compared with the untreated group (48.2% vs. 20.3%,
 < 0.001). In a multivariable logistic regression model, female sex (odds ratio [OR] = 1.71 [CI 1.13-2.59],
 = 0.01) and index thyrotropin (TSH) level (OR = 1.97 [CI 1.56-2.49],
 < 0.001 for every SD [2.75 mIU/L] change) were associated with higher odds of treatment.
Among patients with SCH, female sex and index TSH level were associated with higher odds of treatment. Moreover, in our population, the decision to treat or not to treat SCH was often based on only one set of abnormal TFTs, and thyroid autoimmunity assessment was underused.